Report Overview

The EU Breast cancer drugs market size stood at USD 4.7 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

According to the prediction of the European Cancer Information System (ECIS), breast cancer continues to be the most common female cancer, with the incidence in the EU accounting for 29.2% of all cancers in women. In the EU-28 countries, a total of 404,920 new female breast cancer cases was estimated to occur in 2018, corresponding to an age-adjusted standardized rate (ASR) of 144.9/100,000. Germany dominated the EU market with a market share of around 23% in the year 2018. However, Poland's breast cancer drugs market is estimated to grow with the highest CAGR

The rising prevalence of breast cancer pertaining to factors such as prolonged exposure to endogenous estrogens, early menarche, late age at first childbirth, and late menopause will be a high impact rendering factor for the industry growth



Market Growth Drivers

Growing awareness regarding breast cancer, rising shift towards adoption of western lifestyle, short breast-feeding timeframe, and rising prevalence of obesity in women after menopause will drive the industry size. The increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT), and oral birth control pills resulting in increased levels of estrogen will boost the business size over the forecast period. Increasing technological advances in cancer biology and the launch of several diagnostic and screening programs worldwide should drive the business size

The prohibitive cost associated with the use of breast cancer therapeutics may hamper the industry's growth. Increasing cost of early and late-stage disease therapy, continuing care on a per-unit time basis, accounting for the major share of lifetime cost owing to relatively extended survival of breast cancer patients may further restrain the business growth